Innovative systemic anti-inflammatory treatments.

Transient Pharma develops innovative systemic anti-inflammatory treatments, focusing initially on gastrointestinal inflammatory disorders and curbing the excessive inflammation during acute infections.

Transient Pharma´s groundbreaking research, originating from Professor Artur Schmidtchen’s lab at Lund University, has led to the development of TIM-03, a proprietary peptide with promising therapeutic potential. The peptide has demonstrated multifunctional properties consisting of strong anti-inflammatory effects and antimicrobial effects both in vitro and in vivo.

Did you know?

Our founder Professor Roland Andersson has been active within pancreatic cancer surgery for almost 40 years! 

© 2023 Copyright SmiLe Incubator